Ballentine Partners
LRMR icon

Ballentine Partners’s Larimar Therapeutics LRMR Stock Holding History

Ballentine Partners’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-18,852
Closed -$137K – 867
2024
Q2 		$137K Buy
+18,852
New +$144K ﹤0.01% 713

Other funds holding LRMR

Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Ballentine Partners's LRMR Position: Q3 2024 in Review

Ballentine Partners sold out of Larimar Therapeutics (LRMR) in Q3 2024, closing a stake of 18,852 shares — an estimated $137K sold.

Ballentine Partners first reported a position in LRMR in Q2 2024 and held it in 1 quarter. The position peaked at $137K in Q2 2024. 123 funds tracked by Wall St. Rank hold LRMR as of Q3 2024.

  • Ballentine Partners reported no remaining Larimar Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Ballentine Partners sold 18,852 Larimar Therapeutics shares in Q3 2024, an estimated $137K.
  • Ballentine Partners first reported a position in Larimar Therapeutics in Q2 2024 and held it in 1 quarter.
  • Ballentine Partners's Larimar Therapeutics position peaked at $137K in Q2 2024.
  • 123 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2024.

Based on Ballentine Partners's 13F filing for Q3 2024, filed 23 Oct 2024.